Notice of allowance for patent grant in Japan
Notice of allowance for patent grant in Japan
An important step in the continued protection of Poolbeg’s patent family
Significant progress made and well positioned for future growth
Strong first-half performance and record forward visibility Upgrade of Full Year Revenue and EBITDA Guidance
Plans for a new larger state-of-the-art facility to meet growing demand
hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for
Strong first-half performance and record order book On track to deliver full-year guidance and long-term sustainable growth
£13.1m contract with the global pharmaceutical client to develop an influenza B virus challenge model
Successful Artificial Intelligence led programme identifies multiple influenza drug targets
hVIVO to develop human metapneumovirus (hMPV) challenge model First client of the new hMPV model secured
Next-Generation Oral Vaccine Programme Advancing Through Non-Dilutive Funding